Laughing Gas Shows Promise as Fast-Acting Antidepressant, New Study Finds
December 9, 2025
Brand Name :
Stelfonta
Synonyms :
tigilanol tiglate
Class :
Antineoplastic
Dosage Forms & Strengths:Â
Intratumoral injection Â
1 mg/ml Â
For veterinary use only
Administer intratumoral injection of 0.5 ml per cm3 of total tumor volume
It is indicated for the treatment of mast cell tumors, which are a type of cancer that originates from mast cells.
Pediatric Â
Not determined Â
Refer to adult dosing
Actions and Spectrum:Â
It may induce apoptosis and necrosis in the targeted tumor cells. It activates a cellular signaling pathway, which leads to the destruction of tumor tissue.  Â
The drug is designed to target and treat mast cell tumors in dogs.Â
Black box warning:Â
None Â
Contraindication/Caution:Â
Not For use in humansÂ
Keep this medication out of reach of childrenÂ
Avoid injecting into subcutaneous mast cell tumors located above the elbow or hock of a dogÂ
Pregnancy Warnings:Â Â
Pregnancy category: N/AÂ Â
Lactation:Â Â
Excretion of the drug in human breast milk is unknown Â
Pregnancy categories:Â Â Â Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.   Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.   Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.   Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.   Â
Category N: There is no data available for the drug under this category.     Â
Pharmacology:Â Â
Tigilanol tiglate activates a cellular signaling pathway, and its mechanism of action involves activating protein kinase C (PKC). Â
Pharmacodynamics:Â Â
It produces an inflammatory response at the site of injection. This localized inflammation is part of the therapeutic effect that attracts immune cells to the area.  Â
Pharmacokinetics:Â Â
Limited information is available on ADME.Â
Administration:Â Â
It is administered through a single intratumoral injection directly into the tumor tissue.Â
Patient information leaflet:Â Â
Generic Name: tigilanol tiglate  Â
Why do we use tigilanol tiglate?Â
It is used as veterinary medicine in dogs for the treatment of mast cell tumors.Â